Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers

Data from a retrospective study of patients with metastatic breast and castration-resistant prostate cancer (CRPC) with bone metastases who received bone-modifying agents found that the risk of symptomatic skeletal events (SSEs) was highest during the first year after bone metastasis diagnosis. Among the 59% of breast cancer and 75% of CRPC patients who had ≥ 1 SSE, 38.9% experienced it within the first year after metastasis diagnosis, compared with 17.5% in the second year and 24.4% in the third year.